Cornerstone BioPharma Inc., Critical Therapeutics deal

The companies will merge to form Cornerstone Therapeutics Inc. Cornerstone shareholders will receive 101.5 million Critical shares valued at $63.9 million based on Critical's close of $0.63 on May 1,...